ATARA BIOTHERAPEUTICS, INC. Payments for Royalties
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Payments for Royalties of $230.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRoyalties · last filed 2026-08-12
- ATARA BIOTHERAPEUTICS, INC. payments for royalties for the quarter ending 2026-06-30 was $126.00K, a 147.06% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. payments for royalties for the quarter ending 2026-03-31 was $104.00K.
- ATARA BIOTHERAPEUTICS, INC. payments for royalties for the quarter ending 2025-12-31 was $115.00K, a 0.88% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. payments for royalties for the quarter ending 2025-09-30 was $53.00K, a 13.11% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. payments for royalties for fiscal 2025 was $219.00K, a 10.98% decline from fiscal 2024.
- ATARA BIOTHERAPEUTICS, INC. payments for royalties for fiscal 2024 was $246.00K, a 693.55% increase from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. payments for royalties for fiscal 2023 was $31.00K, a 91.58% decline from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. payments for royalties for fiscal 2022 was $368.00K.
| Period end | Payments for Royalties 3 month | Payments for Royalties 6 month | Payments for Royalties 9 month | Payments for Royalties 12 month |
|---|---|---|---|---|
| 2026-06-30 | $126.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $230.00K 10-Q · filed 2026-08-12 | $345.00K derived: sum of 3 quarters · filed 2026-08-12 | $398.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $104.00K 10-Q · filed 2026-05-12 | $219.00K derived: sum of 2 quarters · filed 2026-05-12 | $272.00K derived: sum of 3 quarters · filed 2026-05-12 | $323.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | $115.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $168.00K derived: sum of 2 quarters · filed 2026-03-16 | $219.00K derived: sum of 3 quarters · filed 2026-03-16 | $219.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $53.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $104.00K derived: sum of 2 quarters · filed 2025-11-12 | $104.00K 10-Q · filed 2025-11-12 | $218.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | $51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $51.00K 10-Q · filed 2025-08-11 | $165.00K derived: sum of 3 quarters · filed 2025-08-11 | $226.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | $114.00K derived: sum of 2 quarters · filed 2025-05-15 | $175.00K derived: sum of 3 quarters · filed 2025-05-15 | $221.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-12-31 | $114.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $175.00K derived: sum of 2 quarters · filed 2025-03-07 | $221.00K derived: sum of 3 quarters · filed 2025-03-07 | $246.00K 10-K · filed 2025-03-07 |
| 2024-09-30 | $61.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $107.00K derived: sum of 2 quarters · filed 2024-11-12 | $132.00K 10-Q · filed 2024-11-12 | $152.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | $46.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $71.00K 10-Q · filed 2024-08-12 | $91.00K derived: sum of 3 quarters · filed 2024-08-12 | $102.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | $25.00K 10-Q · filed 2024-05-09 | $45.00K derived: sum of 2 quarters · filed 2024-05-09 | $56.00K derived: sum of 3 quarters · filed 2024-05-09 | $56.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $31.00K derived: sum of 2 quarters · filed 2024-03-28 | $31.00K derived: sum of 3 quarters · filed 2024-03-28 | $31.00K 10-K · filed 2024-03-28 |
| 2023-09-30 | $11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $11.00K derived: sum of 2 quarters · filed 2023-11-01 | $11.00K 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | ||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $368.00K 10-K · filed 2023-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |